Dual GIP/GLP-1 receptor agonist
Tirzepatide (Mounjaro/Zepbound) is a dual GIP and GLP-1 receptor agonist developed by Eli Lilly, FDA-approved for Type 2 diabetes and chronic weight management. It is one of the most discussed weight loss drugs in biohacking and fitness communities, with clinical trials showing weight loss exceeding 20%.
Track public claims and clinical trial progress. Do not publish dosing, sourcing, or treatment instructions. Separate clinical trial data from social media hype and off-label use discussions.
FDA-approved as Mounjaro for Type 2 diabetes (May 2022) and Zepbound for chronic weight management (November 2023).
SURMOUNT-1 Phase 3 trial showed mean weight loss of 22.5% at 72 weeks at the highest dose, published in NEJM (2022).
SURPASS-2 trial demonstrated superior A1C reduction versus semaglutide in Type 2 diabetes patients.
One of the most prescribed and discussed drugs in the GLP-1 class, with massive social media attention from fitness and biohacking creators.
Ongoing trials are evaluating cardiovascular outcomes, sleep apnea, and liver disease (MASH) indications.
Evidence level: Peer reviewed
Sources: New England Journal of Medicine, ClinicalTrials.gov
Cite the NEJM SURMOUNT-1 publication directly. Results are specific to the trial population and dosing protocol.
Evidence level: Primary regulatory
Sources: U.S. Food and Drug Administration, U.S. Food and Drug Administration
Confirm approval status against FDA records on each review cycle. Track any label changes or new indications.
Evidence level: Peer reviewed
Sources: New England Journal of Medicine
SURPASS-2 compared tirzepatide to semaglutide in Type 2 diabetes. Do not generalize to weight loss comparisons.
Evidence level: Community discussion
Sources: YouTube — Christopher McGowan, MD, YouTube — Dr. Eric Berg DC
Track as media claims that may exceed clinical evidence. Separate approved indications from community hype.
Source records are stored in the repo and linked from each claim.
Phase 3 trial of tirzepatide for obesity showing mean weight loss of 22.5% at 72 weeks at the highest dose.
Head-to-head trial showing tirzepatide superior to semaglutide for A1C reduction in Type 2 diabetes.
ClinicalTrials.gov registry for the SURMOUNT-1 Phase 3 trial of tirzepatide for obesity, sponsored by Eli Lilly.
ClinicalTrials.gov registry for SURMOUNT-4, evaluating tirzepatide for extended obesity treatment.
FDA approval of Mounjaro (tirzepatide) injection for Type 2 diabetes, NDA 215866.
FDA approval of Zepbound (tirzepatide) injection for chronic weight management, NDA 217806.
Medical doctor explainer video on Mounjaro/tirzepatide with significant views. Tracked as media signal for public claim patterns.
High-view video discussing Mounjaro alternatives. Tracked as media signal for alternative-seeking behavior.
Huberman Lab discussion on GLP-1 mechanism. Tracked as expert media signal for public understanding.
Retatrutide is an investigational triple-agonist peptide (GLP-1, GIP, and glucagon receptor agonist) developed by Eli Li...
Regulatory watchSemaglutide (Ozempic/Wegovy/Rybelsus) is a GLP-1 receptor agonist developed by Novo Nordisk, FDA-approved for Type 2 dia...
Evidence review